UBS analysts maintained a Buy rating for Alvotech SA (NASDAQ:ALVO) with a steady price target of $18.00, representing a 41% ...

The second part of our conversation with Craig Burton, MBA, executive director of the Biosimilars Council, a trade and ...

In terms of how Stelara’s loss of exclusivity is likely to play out, “we’ve talked about the Humira erosion curve being probably the best thing to model,” Jennifer Taubert, J&J’s ...

Investors are also waiting to see how generic competition shakes out for Stelara. Using AbbVie's (ABBV) Humira as a guide, the company and analysts alike see potential for a muted impact.

After recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion ...

SAN FRANCISCO -- The pediatric Crohn's disease exclusion diet was associated with clinical remission for children with good ...

AbbVie Inc . (NYSE:ABBV), currently trading at $190.14, has demonstrated resilience and strategic foresight as it navigates the loss of exclusivity for its blockbuster drug Humira. The ...

Investors are also waiting to see how generic competition shakes out for Stelara. Using AbbVie's (ABBV) Humira as a guide, the company and analysts alike see potential for a muted impact. Humira ...

Tariffs and price inflation for specialty medications will increase costs, according to research from Vizient.

While Humira faces further erosion due to biosimilar ... The entry of biosimilars for competitors' products, such as Stelara, may benefit AbbVie by increasing pressure on rivals and potentially ...